The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: 0.50 (2.86%)
Spread: 1.00 (5.714%)
Open: 17.50
High: 18.00
Low: 17.50
Prev. Close: 17.50
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

30 Jan 2023 16:28

RNS Number : 3057O
SkinBioTherapeutics PLC
30 January 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights areattachedii:

 

SKINBIOTHERAPEUTICS PLC

1b. Please indicate if the issuer is a non-UK issuer(please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification(please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

x

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Optibiotix Health Plc

City and country of registered office (if applicable)

UK

4. Full name of shareholder(s)(if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

05/01/2023

6. Date on which issuer notified (DD/MM/YYYY):

30/01/2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights at- tached to shares (to- tal of 8. A)

% of voting rights through financial instru- ments

(total of 8.B 1 + 8.B 2)

 

Total of both in % (8.A + 8.B)

Total number of voting rights of is- suervii

Resulting situation on the date on which

threshold was crossed or reached

 

18.71%

 

173,138,854

Position of previous notification (if applicable)

 

20.67%

 

1

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

32,402,206

18.71%

SUBTOTAL 8. A

32,402,206

18.71%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

 

Type of financial in- strument

 

Expiration datex

 

Exercise/ Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

 

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration datex

Exercise/ Conversion Pe-

riod xi

Physical or cash

settlementxii

Number of voting rights

 

% of voting rights

SUBTOTAL

8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv

(please add additional rows as necessary)

 

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial in- struments if it equals or is higher than the

notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London

Date of completion

30/01/2023

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBMMFTMTTJBAJ
Date   Source Headline
4th Jul 20182:07 pmRNSResult of AGM
4th Jul 20187:00 amRNSDirectorate Change
26th Jun 20187:00 amRNSAgreement with global corporate for SweetBiotix®
21st Jun 20187:00 amRNSExclusive license agreement for LPLDL®
18th Jun 20187:00 amRNSManufacturing agreement with Morley Foods
14th Jun 20187:00 amRNSExercise of Options and Issue of Equity
11th Jun 20187:00 amRNSNotice of AGM
7th Jun 20187:00 amRNSUS launch of LPLDL® with Seed Health
31st May 20187:00 amRNSSweetBiotix® agreement with global dairy company
30th May 20187:00 amRNSPlacing and Issue of Equity
23rd May 20187:00 amRNSFinal Results
22nd May 20187:00 amRNSLP-LDL agreement for USA
18th May 20187:00 amRNSSlimBiome® wins award at Vitafoods 2018
16th May 20184:40 pmRNSHolding(s) in Company
16th May 20187:00 amRNSExclusive manufacturing and supply agreement
8th May 20187:00 amRNSLaunch of extended range of products at Vitafoods
1st May 20187:00 amRNSLP-LDL? news media interest in USA
30th Apr 20187:00 amRNSNotice of Results
24th Apr 20187:00 amRNSSlimBiome non-exclusive UK distribution agreement
19th Apr 20187:00 amRNSAppointment of Head of Online Sales and Marketing
18th Apr 20187:00 amRNSCholBiome exclusive distribution agreement
5th Apr 20187:00 amRNSNew patent filings for SweetBiotix
27th Mar 20187:00 amRNSScientific and commerical update
8th Mar 20187:00 amRNSLaunch of Slimbiome in Nutri-bites
6th Mar 20187:00 amRNSLPLDL® Exclusive European License Agreement
28th Feb 20187:00 amRNSOptiBiotix Capital Reorganisation
6th Feb 20187:00 amRNSExercise of warrant and issue of equity
1st Feb 20182:22 pmRNSDirector's dealing
30th Jan 20183:03 pmRNSExercise of warrant and issue of equity
25th Jan 201811:45 amRNSResult of Meeting
23rd Jan 20187:00 amRNSSweetBiotix® development: human taste studies
17th Jan 20187:00 amRNSPresentation of data at European Conference
8th Jan 20183:12 pmRNSShareholder Circular and Notice of General Meeting
8th Jan 20187:00 amRNSDirectorate Changes
14th Dec 20173:35 pmRNSExercise of warrant and issue of equity
12th Dec 20177:00 amRNSManufacturing, supply & profit sharing agreement
5th Dec 20177:00 amRNSProposed directorate changes
28th Nov 20177:00 amRNSCapital reorganisation
17th Nov 20173:06 pmRNSExercise of Warrant and Issue of Equity
8th Nov 20177:00 amRNSSlimBiome® commercial & product development update
1st Nov 20177:00 amRNSManufacturing, supply & profit sharing agreement
26th Oct 20177:00 amRNSPresentation of research
24th Oct 20177:00 amRNSLPLDL® supply agreement with Galenicum
4th Oct 20177:00 amRNSSuccessful launch of products at Supply Side West
19th Sep 20177:00 amRNSTechnical, regulatory & commercial update
13th Sep 20177:00 amRNSStrategic partnership with Bened Biomedical
11th Sep 201712:00 pmRNSHolding(s) in Company
7th Sep 20177:00 amRNSInvited to present at Expoquimia in Barcelona
6th Sep 20179:30 amRNSInvestor evening
5th Sep 20177:00 amRNSManufacturing Agreement with Tata Chemicals

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.